GCSF-R expression in myelodysplastic and myeloproliferative disorders and blast dysmaturation in CML

American Journal of Clinical Pathology

Volumn 140, Issue 2, 2013, Pages 155-164

  Hanumanthu, Vidya Sagar ^a   Pirruccello, Samuel J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CD114; Chronic myelogenous leukemia; Flow cytometry; GCSF R; Myelodysplastic syndrome

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CELL MATURATION; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION;

CD114; CHRONIC MYELOGENOUS LEUKEMIA; FLOW CYTOMETRY; GCSF-R; MYELODYSPLASTIC SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BONE MARROW; FEMALE; FLOW CYTOMETRY; GRANULOCYTES; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; SIALIC ACID BINDING IG-LIKE LECTIN 3; TUMOR MARKERS, BIOLOGICAL;

EID: 84881256477     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPCLHZR5KUHUBM     Document Type: Article

References (63)

1. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95-120.
2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
3. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727-736.
4. Brunning R, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours and Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:88-93.
5. Valent P, Orazi A, Busche G, et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget. 2010;1:483-496.
6. Cazzola M, la Porta MG, Travaglino E, et al. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol. 2011;38:627-634.
7. Pagnucco G, Vanelli L, Gervasi F. Multidimensional flow cytometry immunophenotyping of hematologic malignancy. Ann N Y Acad Sci. 2002;963:313-321.
8. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol. 2004;4:648-655.
9. Arnoulet C, Bene MC, Durrieu F, et al. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin Cytom. 2010;78:4-10.
10. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica. 1998;83:1104-1115.
11. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98:979-987.
12. Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood. 2002;100:3887-3896.
13. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102:394-403.
14. Arroyo JL, Fernandez ME, Hernandez JM, et al. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes: its value in patients without karyotypic abnormalities. Hematol J. 2004;5:227-233.
15. Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol. 2005;124:170-181.
16. Ogata K, Kishikawa Y, Satoh C, et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood. 2006;108:1037-1044.
17. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia: CD34 and CD117 expression abnormalities are common. Am J Clin Pathol. 2006;125:884-894.
18. van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111:1067-1077.
19. Matarraz S, Lopez A, Barrena S, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008;22:1175-1183.
20. Truong F, Smith BR, Stachurski D, et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res. 2009;33:1039-1046.
21. Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94:1066-1074.
22. Kern W, Haferlach C, Schnittger S, et al. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer. 2010;116:4549-4563.
23. Matarraz S, Lopez A, Barrena S, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom. 2010;78:154-168.
24. Tang G, Jorgensen JL, Zhou Y, et al. Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leuk Res. 2012;36:974-981.
25. Loken MR, van de Loosdrecht A, Ogata K, et al. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res. 2008;32:5-17.
26. van de Loosdrecht AA, Alhan C, Bene MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94:1124-1134.
27. Westers TM, van der Velden VH, Alhan C, et al. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS. Leuk Res. 2012;36:422-430.
28. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26:1730-1741.
29. Touw IP, van de Geijn GJ. Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front Biosci. 2007;12:800-815.
30. Avalos BR. Molecular analysis of the granulocyte colonystimulating factor receptor. Blood. 1996;88:761-777.
31. Ward AC. The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007;12:608-618.
32. Cosman D. The hematopoietin receptor superfamily. Cytokine. 1993;5:95-106.
33. Wells JA, de Vos AM. Hematopoietic receptor complexes. Annu Rev Biochem. 1996;65:609-634.
34. Fukunaga R, Seto Y, Mizushima S, et al. Three different mRNAs encoding human granulocyte colony-stimulating factor receptor. Proc Natl Acad Sci U S A. 1990;87:8702-8706.
35. Fukunaga R, Ishizaka-Ikeda E, Seto Y, et al. Expression cloning of a receptor for murine granulocyte colonystimulating factor. Cell. 1990;61:341-350.
36. Fukunaga R, Ishizaka-Ikeda E, Pan CX, et al. Functional domains of the granulocyte colony-stimulating factor receptor. EMBO J. 1991;10:2855-2865.
37. Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood. 2010;115:5131-5136.
38. Dong F, van Buitenen C, Pouwels K, et al. Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation. Mol Cell Biol. 1993;13:7774-7781.
39. Dong F, Hoefsloot LH, Schelen AM, et al. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci U S A. 1994;91:4480-4484.
40. Dong F, Brynes RK, Tidow N, et al. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487-493.
41. Dong F, Dale DC, Bonilla MA, et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia. 1997;11:120-125.
42. Ward AC, van Aesch YM, Schelen AM, et al. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood. 1999;93:447-458.
43. Hermans MH, Antonissen C, Ward AC, et al. Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia derived mutation in the G-CSF receptor gene. J Exp Med. 1999;189:683-692.
44. Hunter MG, Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood. 1999;93:440-446.
45. Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood. 2000;95:2132-2137.
46. Hunter MG, Jacob A, O'Donnell L C, et al. Loss of SHIP and CIS recruitment to the granulocyte colony-stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia. J Immunol. 2004;173:5036-5045.
47. Wolfler A, Erkeland SJ, Bodner C, et al. A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood. 2005;105:3731-3736.
48. Forbes LV, Gale RE, Pizzey A, et al. An activating mutation in the transmembrane domain of the granulocyte colonystimulating factor receptor in patients with acute myeloid leukemia. Oncogene. 2002;21:5981-5989.
49. Link DC, Kunter G, Kasai Y, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007;110:1648-1655.
50. Beel K, Vandenberghe P. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica. 2009;94:1449-1452.
51. Shinjo K, Takeshita A, Ohnishi K, et al. Granulocyte colonystimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk Lymphoma. 1997;25:37-46.
52. Begley CG, Metcalf D, Nicola NA. Binding characteristics and proliferative action of purified granulocyte colonystimulating factor (G-CSF) on normal and leukemic human promyelocytes. Exp Hematol. 1988;16:71-79.
53. Kimura A, Sultana TA. Granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukemia. Leuk Lymphoma. 2004;45:1995-2000.
54. Lee J, Kim Y, Lim J, et al. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia. Ann Clin Lab Sci. 2008;38:331-337.
55. Yue LZ, Fu R, Wang HQ, et al. Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome. Chin Med J (Engl). 2010;123:2034-2037.
56. Xu H, Li A, Yu Y, et al. Comparative analysis of G-CSFR and GM-CSFR expressions on CD34+ cells in patients with aplastic anemia and myelodysplastic syndrome. Int J Lab Hematol. 2009;31:597-602.
57. Smith LT, Hohaus S, Gonzalez DA, et al. PU.1 (Spi-1) and C/EBPa regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood. 1996;88:1234-1247.
58. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/ EBPa expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30:48-58.
59. Tenen DG, Hromas R, Licht JD, et al. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
60. Ward AC, Loeb DM, Soede-Bobok AA, et al. Regulation of granulopoiesis by transcription factors and cytokine signals. Leukemia. 2000;14:973-990.
61. Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J. 1998;17:4442-4455.
62. Wang X, Scott E, Sawyers CL, et al. C/EBPa bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999; 94:560-571.
63. Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein e-deficient mice. Proc Natl Acad Sci U S A. 1997;94:13187-13192.